Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.83) by 19.28 percent. This is a 110.64 percent decrease over losses of $(0.47) per share from the same period last year. The company reported quarterly sales of $218.400 million which missed the analyst consensus estimate of $221.230 million by 1.28 percent. This is a 45.56 percent increase over sales of $150.042 million the same period last year.